Increased data output from the use of devices can accelerate trials for this therapeutic area in need of new therapies.
Practical suggestions for identifying what actionable insights have been impactful on clinical studies.
These devices can help researchers identify data points that are not immediately available to researchers.
Characterizing the long-term adoption experience of clinical technologies and capabilities—and what senior leaders can do to drive adoption within their walls.
A three-part framework for a more comprehensive conceptual model of patient experience data can provide a more rounded understanding of patient experiences in clinical trials and beyond.
Analysis of 330,000 clinical trials calls for improved protocol design process.
Characterizing the long-term adoption experience of clinical technologies and capabilities—and what senior leaders can do to drive adoption within their walls.
Integrating artificial intelligence and advanced analytics throughout operations offers pharma companies a pathway to offset impending drug patent expirations.
The role of data science, how it can help us understand patient behavior, and why digital adherence solutions are the future.
First-of-its-kind consortium dedicated to accelerating new medicines development through optimizing patient advocacy group—industry collaboration.
Successful collaborations between Pharma/Biotech/Device industries and CROs will play a key role in an effective fight against the global COVID-19 pandemic.
How the inclusion of measures centered on net treatment benefit can drive an effective multifaceted approach.
While Case Report Forms are a main contributor to collected data, non-CRF data such as core laboratory data and central imaging can be critical to any clinical study.
In the rare disease issue of New Medicines, Novel Insights from Parexel, experts and former regulators share insights for developing effective regulatory strategies earlier.
Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.
Master protocols helped accelerate research during the pandemic in the EU. How can US companies learn from this and start preparing master protocols now?
The approach of the Cancer Research UK Centre for Drug Development.
Exploring the 11 key ‘warning signs’ that could impact partnership success.
In a complex world of global clinical trials where execution is riddled with uncertainty, how should sponsors and providers approach and achieve a balance of risk and reward?
Phase I/II study in cancer patients showcases eClinical effectiveness.
Fully-integrated, component-based CDMS offers flexibility, customization, and efficiency.
The use of modeling and biosimulation can help predict potential outcomes and improve confidence in therapeutic candidates for Alzheimer disease.
The many different shapes and sizes of vendors requires a thoughtful process for selection.
Key considerations in deploying fit-for-purpose digital health technologies in drug development.
Pursuing new tools and capabilities in sample logistics, storage, and data analysis.
Emerging tools in data analytics, automation, EMR aggregation, and even social media are enabling faster and easier patient recruitment.
The adaptability and innovative capacity of CROs highlighted in EUCROF survey.
Bringing clinical trials to patients’ homes can address existing site-based challenges.